These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31068365)

  • 1. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
    Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
    Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.
    Shing DC; Trubia M; Marchesi F; Radaelli E; Belloni E; Tapinassi C; Scanziani E; Mecucci C; Crescenzi B; Lahortiga I; Odero MD; Zardo G; Gruszka A; Minucci S; Di Fiore PP; Pelicci PG
    J Clin Invest; 2007 Dec; 117(12):3696-707. PubMed ID: 18037989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
    Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
    Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
    Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
    Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
    Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
    Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
    Hein N; Cameron DP; Hannan KM; Nguyen NN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
    Blood; 2017 May; 129(21):2882-2895. PubMed ID: 28283481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
    Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
    Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
    Yan B; Claxton D; Huang S; Qiu Y
    Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Pulikkottil AJ; Bamezai S; Ammer T; Mohr F; Feder K; Vegi NM; Mandal T; Kohlhofer U; Quintanilla-Martinez L; Sinha A; Buske C; Rawat VPS
    Leukemia; 2022 Feb; 36(2):416-425. PubMed ID: 34462525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice.
    Pourebrahim R; Montoya RH; Akiyama H; Ostermann L; Khazaei S; Muftuoglu M; Baran N; Zhao R; Lesluyes T; Liu B; Khoury JD; Gagea M; Van Loo P; Andreeff M
    Cell Rep Med; 2024 May; 5(5):101558. PubMed ID: 38733986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
    Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
    Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
    Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
    Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
    Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
    J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LGALS1 acts as a pro-survival molecule in AML.
    Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Post SM; Andreeff M
    Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118785. PubMed ID: 32590026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dominant-negative effect drives selection of
    Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
    Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
    [No Abstract]   [Full Text] [Related]  

  • 20. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
    Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
    Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.